Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …

Background and objective Innovations have improved outcomes in advanced prostate
cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …

Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum
bone health throughout the natural course of prostate cancer is an important aspect in the …

Background The effect of longer-term use of bone-modifying agent (BMA) on symptomatic
skeletal event (SSE) rates in patients with bone metastases remains unclear. This …

Objective: This study aims to establish and validate a predictive model for bone metastasis
in prostate cancer patients based on multiple immune inflammatory parameters. Methods: In …

Purpose: To review the successes and challenges of integrating systematic reviews (SRs)
into the Rethinking Clinical Trials (REaCT) Program. Methods: All REaCT program SRs …

Background Prostate cancer (PCa) treatments are associated with a detrimental impact on
bone health (BH) and body composition. However, the evidence on these issues is limited …

Giant cell tumor of bone (GCTB) is a locally aggressive intermediate bone tumor.
Denosumab has shown effectiveness in GCTB treatment; however, the benefits of …

We reviewed patient and health care provider (HCP) surveys performed through the REaCT
program. The REaCT team has performed 15 patient surveys (2298 respondents) and 13 …

Objective: To review published clinical trial data related to efficacy and safety of
administering denosumab at extended dosing intervals for prevention of skeletal-related …